Artery Therapeutics
Artery Therapeutics is a clinical-stage biotechnology company developing CS6253, a first-in-class ABCA1 agonist peptide for APOE4-associated Alzheimer
DeepWEBSITE ↗
Why it's on the radar
TeamFundraising signals (who's likely raising, and why) are on Team.Start a free 14-day trial →Funding history · 0 rounds
No rounds on record yet.
Key people
ProKey people, exec moves and open roles are on Pro.Start a free 14-day trial →